Author

Bayo Lau

ORCID 0000-0001-7243-9221Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Hugo Y. K. LamiD· 2 shared Jackson Chapman· 1 shared Jonathan WarrelliD· 1 shared Karl Podesta· 1 shared Lijing Yao· 1 shared Marghoob Mohiyuddin· 1 shared Mark GersteiniD· 1 shared Paul Willard Merrill· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Hugo Y. K. LamORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Insights from Incorporating Quantum Computing into Drug Design Workflows

Bayo Lau, Prashant S. Emani, Jackson Chapman, Lijing Yao, Tarsus Lam, Paul Willard Merrill, Jonathan Warrell, Mark Gerstein, Hugo Y. K. Lam

This paper introduces HypaCADD, a hybrid classical-quantum workflow for drug design that uses quantum machine learning to predict mutation impacts, showing performance comparable to classical methods.

Bioinformatics · Dec 7, 2022Peer-reviewedBioinformatics

Deep convolutional neural networks for accurate somatic mutation detection

Sayed Mohammad Ebrahim Sahraeian, Ruolin Liu, Bayo Lau, Karl Podesta, Marghoob Mohiyuddin, Hugo Y. K. Lam

NeuSomatic is a convolutional neural network for somatic mutation detection that outperforms existing methods across various sequencing platforms and tumor purities.

Nature Communications · Mar 4, 2019Peer-reviewedGenomics